ESSA Pharma Inc. Files 8-K on Major Corporate Events

TL;DR

ESSA Pharma Inc. 8-K: Acquisition, delisting notice, control change, exec changes filed Oct 9, 2025.

AI Summary

On October 9, 2025, ESSA Pharma Inc. filed an 8-K report detailing several significant events. These include the completion of an acquisition or disposition of assets, a notice of delisting or failure to meet listing standards, material modifications to security holder rights, and changes in control of the registrant. The filing also covers departures of directors or officers, election of directors, appointment of officers, and compensatory arrangements. Additionally, it addresses other events and includes financial statements and exhibits.

Why It Matters

This 8-K filing indicates significant corporate restructuring and potential changes in the company's operational and financial status, which could impact its stock performance and investor confidence.

Risk Assessment

Risk Level: high — The filing mentions a notice of delisting or failure to meet listing standards, which is a significant risk factor for investors.

Key Players & Entities

• ESSA Pharma Inc. (company) — Registrant

FAQ

Key Financial Figures

• $0.1242 — tomatically into the right to receive US$0.1242 per Share, plus one contingent value ri
• $0.14 — right to receive up to approximately US$0.14 per CVR and payable within specified pe
• $6.7 million — of US$0.14 per Share represents up to US$6.7 million in the aggregate that may be distribute

Filing Documents

• tm2528270d1_8k.htm (8-K) — 36KB
• tm2528270d1_ex99-1.htm (EX-99.1) — 13KB
• 0001104659-25-098078.txt ( ) — 219KB
• epix-20251009.xsd (EX-101.SCH) — 3KB
• epix-20251009_lab.xml (EX-101.LAB) — 33KB
• epix-20251009_pre.xml (EX-101.PRE) — 22KB
• tm2528270d1_8k_htm.xml (XML) — 4KB

01 Completion of Acquisition or Disposition of Assets

Item 2.01 Completion of Acquisition or Disposition of Assets. The information provided in the Introductory Note is incorporated by reference herein. in the Agreement and the Arrangement, on October 9, 2025, each Share outstanding immediately prior to the effective time of the Arrangement (the "Effective Time") was converted automatically into the right to receive US$0.1242 per Share, plus one contingent value right ("CVR") per Share, which CVR represents the right to receive up to approximately US$0.14 per CVR and payable within specified periods following the close of the Arrangement. The potential CVR payment of US$0.14 per Share represents up to US$6.7 million in the aggregate that may be distributed to CVR holders depending on the outcome and related expenses of certain contingent liabilities. The foregoing summary description of the completion of the Arrangement does not purport to be complete and is qualified in its entirety by reference to the terms of the Agreement, which was filed as Exhibit 2.1 to the Current Report on Form 8-K filed by the Company with the SEC on July 14, 2025, including the Amendment Agreement, which was filed as Exhibit 2.1 to the Current Reports on Form 8-K filed by the Company with the SEC on September 24, 2025.

01 Completion of Acquisition or

Item 3.01 Completion of Acquisition or Disposition of Assets. The information set forth under Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference into this Item 3.01. In connection with the consummation of the Arrangement, the Company (i) notified the Nasdaq Capital Market LLC ("Nasdaq") of the consummation of the Arrangement and (ii) requested that Nasdaq (A) suspend trading of the Shares effective before the opening of trading on October 10, 2025 and (B) file with the SEC a Notification of Removal from Listing and/or Registration on Form 25 to effect the delisting of all Shares from Nasdaq and the deregistration of such Shares under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In addition, Purchaser intends to file a Certification and Notice of Termination of Registration on Form 15 with the SEC requesting the termination of registration of the Shares under Section 12(g) of the Exchange Act and the suspension of reporting obligations under Sections 13 and 15(d) of the Exchange Act with respect to the Shares.

03 Material Modification to Rights of Security Holders

Item 3.03 Material Modification to Rights of Security Holders. The information set forth under Items 2.01, 5.01 and 5.02 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03.

01 Changes in Control of Registrant

Item 5.01 Changes in Control of Registrant. The information set forth under Items 2.01 and 5.02 of this Current Report on Form 8-K is incorporated by reference into this Item 5.01. As a result of the consummation of the Arrangement, there was a change in control of the Company, and the Company became a wholly owned subsidiary of Purchaser.

02 Departure of Directors; Election of Directors; Appointment of Certain Officers

Item 5.02 Departure of Directors; Election of Directors; Appointment of Certain Officers. In connection with the Arrangement and pursuant to the terms of the Agreement, at the Effective Time, each of the directors of the Company resigned from the board of directors of the Company. Pursuant to the terms of the Agreement, at the Effective Time, the sole director of Purchaser became the sole director of the surviving corporation following the completion of the Arrangement. The sole director of Purchaser immediately prior to the Effective Time was Jon Adkins. The sole officer of Purchaser immediately prior to the Effective Time was Jon Adkins, serving as President, Treasurer and Secretary.

01 Other Events

Item 8.01 Other Events. On October 9, 2025, the Company issued a press release announcing the closing of the Arrangement. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of ESSA Pharma Inc. issued on October 9, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ESSA PHARMA INC. (Registrant) Date: October 9, 2025 By: /s/ David Wood Name: David Wood Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR